secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-05-21T21:00:16+00:00
Accession:  0001919246-26-000078
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics dismisses CFO Knuettel, appoints Grant Thornton as auditor
-------------------------------------------------------------------------------

- CFO Francis Knuettel II terminated effective April 10, 2026; separation agreement provides $430,000 severance (12 months salary) and accelerated vesting of 59,500 options and 19,525 RSUs.
- Auditor change: CBIZ CPAs dismissed, Grant Thornton LLP engaged for FY2026; no disagreements or reportable events reported.
- Knuettel's equity acceleration: 59,500 options and 19,525 RSUs vest; options exercisable until Jan 15, 2027, unvested portion forfeited.
- Separation agreement includes release of claims, confidentiality, non-disparagement, and cooperation; effective after 7-day revocation period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000078/0001919246-26-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000078/pths-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001919246-26-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer